All In Biotech

Drug Trial Radar · NCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)

Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

358

Planned (sponsor's estimate)

Start

May 30, 2023

Primary completion

Nov 12, 2025

Study completion Apr 24, 2027

Sponsor

Lead sponsor
GI Innovation, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Apr 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Soft Tissue Sarcoma (STS)
  • Platinum-resistant Ovarian Cancer (PROC)
  • Hepatocellular Carcinoma (HCC)
  • Colorectal Cancer (CRC)
  • HER2 Negative Breast Cancer
  • Cutaneous Melanoma
  • Renal Cell Carcinoma (RCC)

Interventions

  • GI-102 subcutaneous (SC)Drug

    0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).

  • GI-102Drug

    Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

  • doxorubicinDrug

    Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.

  • paclitaxelDrug

    Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.

  • bevacizumabDrug

    Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.

  • eribulinDrug

    Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.

  • trastuzumab deruxtecan (T-DXd)Drug

    T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.

  • pembrolizumabDrug

    pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.

  • GI-102Drug

    Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose escalation phase of Part A and B)Time frame: Study Day 1, assessed up to DLT period (3 weeks after treatment)
  2. Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs) (dose escalation phase of Part A and B)Time frame: Study Day 1, assessed up to approximately 24 months
  3. Objective Response Rate (ORR) (dose optimization phase of Part A, dose expansion phase of Part B, Part C and D)Time frame: Study Day 1, assessed up to approximately 24 months

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Scottsdale, Arizona · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Mayo Clinic in Minnesota

    Rochester, Minnesota · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Yonsei University Health System, Severance Hospital

    Seoul, South Korea · Recruiting

  • Yonsei University Health System, Severance Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, Seoul, South Korea · Recruiting

  • St. Vincent's Hospital

    Suwon, suwon, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.